Sector News

UCB sells generics unit Kremers Urban for $1.53 billion

November 7, 2014
Life sciences
UCB is selling its US specialty generics business Kremers Urban Pharmaceuticals to two private equity groups for almost $1.53 billion.
 
The cash from Advent International and Avista Capital Partners will be used by Belgium-headquartered UCB “to reduce indebtedness and increase the company’s capacity strategic investments”. The deal is expected to close by the first quarter of 2015.
 
Kremers Urban focuses on difficult, ‘high-barrier-to-entry’ generics and UCB got hold of the New Jersey-based business through its acquisition of Schwarz Pharma in 2006.
 
UCB chief financial officer Detlef Thielgen said it “has been an important enabler” to build the group’s operations. However, “it’s now the right time from a value perspective to focus on our core business” of neurology and immunology.
 
The sale was announced after another Belgian firm, the over-the-counter group Omega Pharma, announced it was being acquired by Perrigo in a deal worth $4.5 billion.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”